Synpromics wins ‘best emerging UK synthetic biotech company’ at OBN Awards

Published: 6 October 2017

Synpromics, recently relocated to Roslin Innovation Centre, and is thrilled to announce they have been awarded Best Emerging UK Synthetic Biotech Company at the 9th Annual OBN Awards.

The company was nominated on the strength of being the leader in gene control, improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data-driven design.

The OBN Awards celebrate innovation and outstanding achievement across the UK Life Sciences industry, including emerging to late-stage R&D companies as well as life science investors. The Awards cover Biotech, Medtech, Synthetic Biology and Digital Health.

We could not be happier with the outcome of last night’s Awards. This accolade is testament to the significant progress we have made over the past year, in growing our business by expanding the number of partnerships that we have with top pharma and biotech companies and significantly expanding our team.

Michael Roberts, Founder & CSO of Synpromics

OBN is the Membership organisation supporting and bringing together the UK’s innovative life sciences companies, corporate partners and investors.

Further information on Synpromics.

Corporate Contact:
Dr Michael Roberts, CSO
Synpromics Ltd
T: +44 (0)131 651 9667
E: info@synpromics.com

PR Contact:

Deborah Cockerill / Emma Pickup
Sciad Communications Ltd
T: +44 (0)20 7470 8801
E: synpromics@sciad.com

Share

Latest tweets

follow us @MidlothScience

Roslin Innovation Centre

  • The University of Edinburgh
  • Easter Bush Campus
  • Midlothian EH25 9RG

Chief Executive Officer: John Mackenzie

T: +44 (0)131 651 9000

Email us